April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed

Company Enters into Collaborative Research Agreement with NIAID and Company to Run Phase 2a/b Trials in EU
BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that simultaneously modulates inflammation and boosts immune function announced that its recently closed convertible note round was oversubscribed by investors.

Read article here.